Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea
SELEXYS PHARMACEUTICALS CORPORATION · Department of Health and Human Services
Phase II2012$3,112,914
DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle…